

Cannabinoids for spasticity associated with multiple sclerosis

EXCEPTIONAL FUNDING REQUIRED

NHS Swindon has considered the evidence for the use of cannabinoids for spasticity associated with multiple sclerosis (MS) and considers that the clinical effectiveness, likely cost effectiveness and affordability for the use of Sativex[®] is insufficient to support its routine use and therefore cannabinoids for spasticity associated with multiple sclerosis (MS) is not normally funded.